Pharmacia leridistim
Executive Summary
Company discontinues Phase III trial of leridistim for the treatment of complications associated with chemotherapy treatment. The hematopoietic growth factor promoted neutrophil recovery after chemotherapy at least as well as the comparator did, but the primary endpoint of febrile neutropenia was confounded on the leridistim arm by drug-related side effect of fever. The fever led to a higher rate of febrile neutropenia in the leridistim group